CATALENT INC. DL-,01/ US1488061029 /
06/11/2024 21:36:52 | Chg. +2.350 | Volume | Bid22:00:02 | Ask22:00:02 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
55.800EUR | +4.40% | 0 Turnover: 0.000 |
-Bid Size: - | -Ask Size: - | 10.14 bill.EUR | - | - |
GlobeNewswire
28/05
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of...
GlobeNewswire
17/05
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of...
GlobeNewswire
14/05
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
GlobeNewswire
08/05
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cance...
GlobeNewswire
26/04
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger – CTLT, MGRC, CHRD, HRT
GlobeNewswire
11/04
Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings
GlobeNewswire
04/04
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger – NS, CTLT, SCX, EVBG
GlobeNewswire
07/03
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. -...
GlobeNewswire
01/03
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of...
GlobeNewswire
01/03
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of...
GlobeNewswire
28/02
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. -...